Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Clinical trial NCT02108951 · TERMINATED
Trial details
- NCT number
- NCT02108951
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-07
- Primary completion
- 2016-08-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.